AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.

Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.

Studies are unfeasible, sponsors argue in advance of US advisory committee meeting that could lead to FDA ending its waiver on requiring clinical trials in pediatric patients for new testosterone replacement therapy products.

Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.